ArticleJournal of cheminformatics2014
Proteochemometric modeling in a Bayesian framework.
Article in Journal of cheminformatics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 45 citations in OpenAlex.
- To What Extent Can We Extrapolate Proteochemometric Models: A Case Study for the SLC6 Transporter Family.Molecular informatics · 2026Article
- A study of the interaction space of two lactate dehydrogenase isoforms (LDHA and LDHB) and some of their inhibitors using proteochemometrics modeling.BMC chemistry · 2023Article
- How to approach machine learning-based prediction of drug/compound-target interactions.Journal of cheminformatics · 2023Article
- Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.Clinical proteomics · 2022Article
- Applications of Artificial Intelligence in Drug Design: Opportunities and Challenges.Methods in molecular biology (Clifton, N.J.) · 2022Review
- The effect of noise on the predictive limit of QSAR models.Journal of cheminformatics · 2021Article
- Comparing Multiple Machine Learning Algorithms and Metrics for Estrogen Receptor Binding Prediction.Molecular pharmaceutics · 2018Article
- Finding the molecular scaffold of nuclear receptor inhibitors through high-throughput screening based on proteochemometric modelling.Journal of cheminformatics · 2018Article
- PyBioMed: a python library for various molecular representations of chemicals, proteins and DNAs and their interactions.Journal of cheminformatics · 2018Article
- ChemSAR: an online pipelining platform for molecular SAR modeling.Journal of cheminformatics · 2017Article
- Open Source Bayesian Models. 3. Composite Models for Prediction of Binned Responses.Journal of chemical information and modeling · 2016Article
- Identification of binding sites and favorable ligand binding moieties by virtual screening and self-organizing map analysis.BMC bioinformatics · 2015Article
- Prediction of the potency of mammalian cyclooxygenase inhibitors with ensemble proteochemometric modeling.Journal of cheminformatics · 2015Article
- ChemDes: an integrated web-based platform for molecular descriptor and fingerprint computation.Journal of cheminformatics · 2015Article
- Chemically Aware Model Builder (camb): an R package for property and bioactivity modelling of small molecules.Journal of cheminformatics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteochemometrics (PCM) is an approach for bioactivity predictive modeling which models the relationship between protein and chemical information. Gaussian Processes (GP), based on Bayesian inference, provide the most objective estimation of the uncertainty of the predictions, thus permitting the evaluation of the applicability domain (AD) of the model. Furthermore, the experimental error on bioactivity measurements can be used as input for this probabilistic model. In this study, we apply GP implemented with a panel of kernels on three various (and multispecies) PCM datasets. The first dataset consisted of information from 8 human and rat adenosine receptors with 10,999 small molecule ligands and their binding affinity. The second consisted of the catalytic activity of four dengue virus NS3 proteases on 56 small peptides. Finally, we have gathered bioactivity information of small molecule ligands on 91 aminergic GPCRs from 9 different species, leading to a dataset of 24,593 datapoints with a matrix completeness of only 2.43%. GP models trained on these datasets are statistically sound, at the same level of statistical significance as Support Vector Machines (SVM), with [Formula: see text] values on the external dataset ranging from 0.68 to 0.92, and RMSEP values close to the experimental error. Furthermore, the best GP models obtained with the normalized polynomial and radial kernels provide intervals of confidence for the predictions in agreement with the cumulative Gaussian distribution. GP models were also interpreted on the basis of individual targets and of ligand descriptors. In the dengue dataset, the model interpretation in terms of the amino-acid positions in the tetra-peptide ligands gave biologically meaningful results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.